Clinical End Points for Developing Pharmaceuticals to Manage Patients with a Sporadic or Genetic Risk of Colorectal Cancer | oneFAPvoice

welcome to oneFAPvoice

- a positively charged Familial Adenomatous Polyposis community.
  • join today!
scientific articles

Clinical End Points for Developing Pharmaceuticals to Manage Patients with a Sporadic or Genetic Risk of Colorectal Cancer

key information

source: Expert review of gastroenterology & hepatology

year: 2012

authors: Rial N S, Zell J A, Cohen A M, Gerner E W

summary/abstract:

To reduce the morbidity and mortality from colorectal cancer (CRC), current clinical practice focuses on screening for early detection and polypectomy as a form of secondary prevention, complemented with surgical interventions when appropriate. No pharmaceutical agent is currently approved for use in clinical practice for the management of patients at risk for CRC. This article will review earlier attempts to develop pharmaceuticals for use in managing patients with a sporadic or genetic risk of CRC. It will also discuss therapeutic end points under evaluation in current efforts to develop drugs for treating CRC risk factors.

organization: The University of Arizona Medical Center

DOI: 10.1586/egh.12.23

read more full text source

expertly curated content related to this topic

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close